EP1166796A3 - Agents for preventing and treating thrombocytopenia - Google Patents

Agents for preventing and treating thrombocytopenia Download PDF

Info

Publication number
EP1166796A3
EP1166796A3 EP01119790A EP01119790A EP1166796A3 EP 1166796 A3 EP1166796 A3 EP 1166796A3 EP 01119790 A EP01119790 A EP 01119790A EP 01119790 A EP01119790 A EP 01119790A EP 1166796 A3 EP1166796 A3 EP 1166796A3
Authority
EP
European Patent Office
Prior art keywords
agents
preventing
treating thrombocytopenia
thrombocytopenia
pth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01119790A
Other languages
German (de)
French (fr)
Other versions
EP1166796A2 (en
Inventor
Masahiko Tamura
Yasuhiro Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP1166796A2 publication Critical patent/EP1166796A2/en
Publication of EP1166796A3 publication Critical patent/EP1166796A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seal Device For Vehicle (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Forklifts And Lifting Vehicles (AREA)

Abstract

Agents for preventing and treating thrombocytopenia, thrombocytopenic purpura and various diseases that tend to cause bleeding due, presumably, to thrombocytopenia contain a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
EP01119790A 1996-02-01 1997-02-03 Agents for preventing and treating thrombocytopenia Withdrawn EP1166796A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1670196 1996-02-01
JP1670196 1996-02-01
EP97901818A EP0878201B1 (en) 1996-02-01 1997-02-03 Medicaments for the treatment or prevention of thrombocytopenia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP97901818A Division EP0878201B1 (en) 1996-02-01 1997-02-03 Medicaments for the treatment or prevention of thrombocytopenia

Publications (2)

Publication Number Publication Date
EP1166796A2 EP1166796A2 (en) 2002-01-02
EP1166796A3 true EP1166796A3 (en) 2002-03-06

Family

ID=11923601

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01119790A Withdrawn EP1166796A3 (en) 1996-02-01 1997-02-03 Agents for preventing and treating thrombocytopenia
EP97901818A Expired - Lifetime EP0878201B1 (en) 1996-02-01 1997-02-03 Medicaments for the treatment or prevention of thrombocytopenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP97901818A Expired - Lifetime EP0878201B1 (en) 1996-02-01 1997-02-03 Medicaments for the treatment or prevention of thrombocytopenia

Country Status (6)

Country Link
US (3) US6342477B1 (en)
EP (2) EP1166796A3 (en)
AT (1) ATE219374T1 (en)
AU (1) AU1558197A (en)
DE (1) DE69713485T2 (en)
WO (1) WO1997027870A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903194B1 (en) 1996-09-26 2005-06-07 Chungai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
US20020165363A1 (en) 1997-05-15 2002-11-07 Koh Sato Cachexia remedy
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
AU5708500A (en) * 1999-07-02 2001-01-22 Chugai Seiyaku Kabushiki Kaisha Remedies for diseases caused by pth or pthrp
DE60024118T2 (en) * 1999-09-20 2006-07-27 Eli Lilly And Co., Indianapolis USE OF A PARATHYROID HORMONE TO REDUCE CANCER RISK
WO2001082968A1 (en) 2000-04-28 2001-11-08 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
JP4750416B2 (en) * 2002-07-25 2011-08-17 ザ ジェネラル ホスピタル コーポレイション Activation of parathyroid hormone receptor and proliferation of hematopoietic progenitor cells
US7635477B2 (en) * 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
JP4607010B2 (en) 2003-02-28 2011-01-05 中外製薬株式会社 Protein-containing stabilized preparation
ZA200509718B (en) 2003-05-30 2007-03-28 Gemin X Biotechnologies Inc Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US7244709B2 (en) 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
AU2005244734A1 (en) * 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
EP1817056B1 (en) * 2004-11-11 2014-08-13 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
EP1853255A4 (en) * 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada Methods for treating arthritis using triheterocyclic compounds
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2010039872A1 (en) * 2008-10-01 2010-04-08 The Board Of Trustees Of The University Of Illinois Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
EP0539491A1 (en) 1990-07-13 1993-05-05 The Regents Of The University Of California PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No Search *

Also Published As

Publication number Publication date
US20020058626A1 (en) 2002-05-16
WO1997027870A1 (en) 1997-08-07
US7268110B2 (en) 2007-09-11
EP0878201A4 (en) 1999-11-10
US6956022B2 (en) 2005-10-18
EP0878201B1 (en) 2002-06-19
US6342477B1 (en) 2002-01-29
EP1166796A2 (en) 2002-01-02
ATE219374T1 (en) 2002-07-15
US20050197296A1 (en) 2005-09-08
AU1558197A (en) 1997-08-22
DE69713485T2 (en) 2003-01-30
DE69713485D1 (en) 2002-07-25
EP0878201A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
EP1166796A3 (en) Agents for preventing and treating thrombocytopenia
GR3030451T3 (en) Synergistic termiticidal composition of pyrethroid and n-phenyl-pyrazole
EP0857718A4 (en) Endothelin antagonist
IL140849A0 (en) Synergistic and residual pesticidal composition containing plant essential oils
CA2194167A1 (en) Hair-growing agent
BG103790A (en) Hydrophilic binary systems for cyclosporine reception
EP0221732A3 (en) Sustained release tablets
ZA97785B (en) Emulsifier system for rosin sizing agents.
EP0868916A3 (en) Reduction inhibitory agent for active-oxygen eliminating activity
EP0656030A4 (en) Stabilizer system for thiol-ene and thiol-nene compositions.
GR3023440T3 (en) Synergistic agents for controlling insects and mites.
HUP9700926A3 (en) Vitamine d3 analogues, process for producing them and pharmaceutial compositions containing the same
MY105742A (en) A poison bait for control of noxious insects.
GR1002768B (en) Poisoned baits for use against pests
ZA966579B (en) O/W emulsion composition for eye drops.
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
ZA978638B (en) Antimycotic agents having high active compound release.
DE69818834D1 (en) PREVENT OR DELAY HAIR GROWTH
GR1002666B (en) Pesticidal compositions in paste form.
AU679249B2 (en) Fuming, hot-vaporizing insecticide for killing flies, and method for killing flies with the same
ZA974328B (en) Formulation comprising microparticles, for inhalation.
ZA9610841B (en) 2-Pyrazolyloxyphenylacetic acid derivatives, compisitions containing these and their use for fungal and pest control.
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
EP1018336A4 (en) Carcinostatics
ZA936861B (en) Methods and agents for combating cockroaches.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 878201

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20020905

AKX Designation fees paid

Free format text: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021025

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030507